{ "items": [ "\n\n
\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nWe research genetic diseases of the heart (cardiomyopathies) that can lead to sudden cardiac death. An example of an individual with cardiomyopathy is the professional football player Fabrice Muamba, who collapsed on the pitch and had to be resuscitated. He was fortunate to survive his cardiac arrest and his case was featured in the media.
\n \n\n \n \n\n \n\n \n \n \n \n Acute Multidisciplinary Imaging and Interventional Centre\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nThis translational science laboratory aims to understand the functionally important heterogeneity in human cardiovascular disease to allow stratification of pathology and enable targeted therapies.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nDefining the function of new causal atherosclerosis genes from CAD GWAS loci using in vitro and in vivo models.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur programme of work aims to understand nitric oxide (NO) and redox signalling in healthy and diseased myocardium, with a particular focus on atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF). Building on the resources and original discoveries that we have made recently, we plan to test novel interventions that aim to correct the myocardial substrate that promotes the new onset of AF, or HFpEF, or prevent the adverse atrial remodelling that is induced by AF.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n \n \n Oxford Centre for Clinical Magnetic Resonance Research\n \n \n\n \n\n\n
\n \n \n \nWe investigate diseases of the heart valves \u2013 how widespread the problem is, what the causes are, who is at risk from future problems and what treatments can improve outcomes for patients.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n \n \n Oxford Centre for Clinical Magnetic Resonance Research\n \n \n\n \n\n\n
\n \n \n \nWe use multi-parametric cardiac magnetic resonance imaging and multinuclear magnetic resonance spectroscopy to non-invasively investigate the relationship between cardiac metabolism and cardiac function.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur group aims to understand the microRNA-mediated mechanisms fundamental to cardiac fibrosis and electrical remodelling that are associated with atrial fibrillation (a very common rhythm disorder). We are particularly interested in functional cross-talk between two major cell types in the heart \u2013 myocytes and fibroblasts.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nVascular Mechanotransduction in health and disease.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur research is devoted to advancing the science of healthcare delivery for management of major cardiovascular conditions and harnessing the power of Big Data to drive change. Large healthcare datasets are being used to create more transparency about healthcare performance and for better risk stratification of populations for more targeted interventions.
\n \n\n \n \n\n \n\n \n \n \n \n Division of Cardiovascular Medicine\n \n \n\n \n\n\n
\n \n \n \nOur group studies the interplay between adipose tissue and the cardiovascular system. Using translational approaches, we develop novel diagnostic tools for the early detection of cardiovascular diseases and risk stratification. We also work towards the discovery of new therapeutic targets for the prevention and treatment of cardiovascular diseases, in the context of obesity and diabetes.
\n \n\n \n \n